Hansoh Pharma and Roche forge global alliance to advance CDH17-targeting ADCs for solid tumors
SOPHIA ANTIPOLIS, France – October 24, 2025 │ Hansoh Pharmaceutical has signed a license agreement with Roche to develop HS-20110, a CDH17-targeting antibody-drug conjugate (ADC) utilizing a clinically validated topoisomerase inhibitor payload. Hansoh Pharma gives Roche an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan) to advance the clinical development and[…]